Glenmark Pharmaceuticals Ltd.’s teneligliptin effectively changed market dynamics in the Indian gliptins segment in 2015 when it made a debut at a price that was 55% lower than the other DPP4 inhibitors at the time – teneligliptin volumes have since surged, overshadowing peers in the class. And the Mumbai-based company now appears to be hoping for a similar run with another diabetes therapy, remogliflozin etabonate, that has hit the Indian market backed by an aggressive cut-price approach.
[Sidebar#SC099667]







